Impact of breakthrough therapy designation on cancer drug development

被引：0
|
作者：
Michael Shea
Linda Ostermann
Ryan Hohman
Samantha Roberts
Marina Kozak
Ryan Dull
Jeff Allen
Ellen Sigal
机构：
[1] Friends of Cancer Research,
来源：
Nature Reviews Drug Discovery | 2016年 / 15卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：152 / 152
相关论文
共 50 条
  • [1] Impact of breakthrough therapy designation on cancer drug development
    Shea, Michael
    Ostermann, Linda
    Hohman, Ryan
    Roberts, Samantha
    Kozak, Marina
    Dull, Ryan
    Allen, Jeff
    Sigal, Ellen
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (03) : 152 - 152
  • [2] Drug Development in Serious Diseases: The New "Breakthrough Therapy" Designation
    Woodcock, J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (05) : 483 - 485
  • [3] Expediting Drug Development - The FDA's New "Breakthrough Therapy" Designation
    Sherman, Rachel E.
    Li, Jun
    Shapley, Stephanie
    Robb, Melissa
    Woodcock, Janet
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (20): : 1877 - 1880
  • [4] Accelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed?
    Yao, James C.
    Meric-Bernstam, Funda
    Lee, J. Jack
    Eckhardt, S. Gail
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (16) : 4305 - 4308
  • [5] The Impact of Breakthrough Therapy Designation on Development and Approval of Drugs and Biologics Intended for USE in Pediatric Cancer
    Casey, D.
    Barone, A.
    Marcus, L.
    Baird, K.
    Singh, S.
    Reaman, G.
    [J]. PEDIATRIC BLOOD & CANCER, 2020, 67 : S222 - S222
  • [6] Assessing the Impact of US Food and Drug Administration Breakthrough Therapy Designation Timing on Trial Characteristics and Development Speed
    Pregelj, Lisette
    Hine, Damian C.
    Kesselheim, Aaron S.
    Darrow, Jonathan J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (04) : 1018 - 1024
  • [7] The Impact of Breakthrough Therapy Designation on Development Strategies and Timelines for Nononcology Drugs and Vaccines
    Poirier, A. F.
    Murphy, W. R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (06) : 603 - 605
  • [8] Influence of Breakthrough Therapy Designation in the United States on Oncology Drug Development Timelines in Japan
    Tanaka M.
    Matsumaru N.
    Tsukamoto K.
    [J]. Pharmaceutical Medicine, 2018, 32 (3) : 201 - 207
  • [9] Breakthrough therapy designation for pancreatic cancer vaccine combo
    不详
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (10) : 2779 - 2780
  • [10] Breakthrough Therapy Designation for NewDrugs
    Benz, Edward J., Jr.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (19): : 2042 - 2042
12345